S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:DYAI

Dyadic International (DYAI) Stock Forecast, Price & News

$2.28
+0.05 (+2.24%)
(As of 05/31/2023 ET)
Compare
Today's Range
$2.19
▼
$2.30
50-Day Range
$1.34
▼
$2.28
52-Week Range
$1.12
▼
$3.56
Volume
31,698 shs
Average Volume
33,354 shs
Market Capitalization
$65.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Dyadic International MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
163.2% Upside
$6.00 Price Target
Short Interest
Healthy
2.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.06mentions of Dyadic International in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.14) to $0.11 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

520th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

80th out of 167 stocks

See Top Rated MarketRank™ Stocks Here

DYAI stock logo

About Dyadic International (NASDAQ:DYAI) Stock

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.

Receive DYAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter.

DYAI Stock News Headlines

May 26, 2023 | americanbankingnews.com
Q2 2023 Earnings Forecast for Dyadic International, Inc. Issued By HC Wainwright (NASDAQ:DYAI)
May 24, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Dyadic International (DYAI)
June 1, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
May 17, 2023 | americanbankingnews.com
Dyadic International, Inc. (NASDAQ:DYAI) Sees Large Growth in Short Interest
May 16, 2023 | americanbankingnews.com
FY2023 EPS Estimates for Dyadic International, Inc. Boosted by Analyst (NASDAQ:DYAI)
May 14, 2023 | americanbankingnews.com
Contrasting Zura Bio (NASDAQ:ZURA) and Dyadic International (NASDAQ:DYAI)
May 12, 2023 | finance.yahoo.com
Dyadic International (NASDAQ:DYAI) shareholders are up 12% this past week, but still in the red over the last three years
May 11, 2023 | finance.yahoo.com
DYAI: Abundant Opportunities in Products and Animal & Human Health
June 1, 2023 | Legacy Research (Affiliate) (Ad)
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
May 10, 2023 | finance.yahoo.com
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 10, 2023 | finance.yahoo.com
Dyadic to Participate at Two Industry Events in May
May 9, 2023 | marketwatch.com
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus(TM)
May 8, 2023 | finance.yahoo.com
Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™
April 26, 2023 | finance.yahoo.com
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
April 18, 2023 | finance.yahoo.com
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
April 12, 2023 | finance.yahoo.com
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
April 5, 2023 | americanbankingnews.com
Dyadic International, Inc. (NASDAQ:DYAI) Sees Significant Increase in Short Interest
April 1, 2023 | finance.yahoo.com
Dyadic International, Inc. (NASDAQ:DYAI) Q4 2022 Earnings Call Transcript
April 1, 2023 | finance.yahoo.com
Dyadic International Full Year 2022 Earnings: Revenues Disappoint
March 30, 2023 | finance.yahoo.com
DYAI: 2022 Results
March 30, 2023 | finance.yahoo.com
Dyadic to Present at World Vaccine Congress Washington 2023
March 29, 2023 | finance.yahoo.com
Dyadic Reports 2022 Year End Results and Recent Company Progress
March 28, 2023 | americanbankingnews.com
Dyadic International (DYAI) Scheduled to Post Quarterly Earnings on Wednesday
March 15, 2023 | finance.yahoo.com
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
March 7, 2023 | finance.yahoo.com
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
March 1, 2023 | finance.yahoo.com
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
February 2, 2023 | finance.yahoo.com
Dyadic to Participate in Two Upcoming Investor Conferences
See More Headlines
Receive DYAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter.

DYAI Company Calendar

Last Earnings
3/29/2023
Today
5/31/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DYAI
CUSIP
N/A
CIK
1213809
Web
www.dyadic.com
Phone
(561) 743-8333
Fax
561-743-8343
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+163.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,730,000.00
Net Margins
-251.43%
Pretax Margin
-251.43%
Return on Equity
-68.23%
Return on Assets
-55.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.83
Quick Ratio
6.83

Sales & Book Value

Annual Sales
$2.93 million
Price / Sales
22.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.37 per share
Price / Book
6.16

Miscellaneous

Outstanding Shares
28,810,000
Free Float
21,032,000
Market Cap
$65.69 million
Optionable
Not Optionable
Beta
0.69

Key Executives

  • Mark A. EmalfarbMark A. Emalfarb
    President, Chief Executive Officer & Director
  • Ping W. RawsonPing W. Rawson
    Chief Financial Officer
  • Ronen Tchelet
    Vice President-Research & Business Development
  • Joseph P. Hazelton
    Chief Business Officer

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













DYAI Stock - Frequently Asked Questions

Should I buy or sell Dyadic International stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DYAI shares.
View DYAI analyst ratings or view top-rated stocks.

What is Dyadic International's stock price forecast for 2023?

2 brokerages have issued 1 year target prices for Dyadic International's stock. Their DYAI share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 163.2% from the stock's current price.
View analysts price targets for DYAI or view top-rated stocks among Wall Street analysts.

How have DYAI shares performed in 2023?

Dyadic International's stock was trading at $1.23 at the beginning of the year. Since then, DYAI stock has increased by 85.4% and is now trading at $2.28.
View the best growth stocks for 2023 here.

Are investors shorting Dyadic International?

Dyadic International saw a decrease in short interest in May. As of May 15th, there was short interest totaling 448,500 shares, a decrease of 5.3% from the April 30th total of 473,600 shares. Based on an average daily trading volume, of 39,000 shares, the short-interest ratio is currently 11.5 days. Approximately 2.2% of the company's shares are sold short.
View Dyadic International's Short Interest.

When is Dyadic International's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our DYAI earnings forecast.

How were Dyadic International's earnings last quarter?

Dyadic International, Inc. (NASDAQ:DYAI) released its earnings results on Wednesday, March, 29th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The biotechnology company earned $0.74 million during the quarter, compared to the consensus estimate of $1.45 million. Dyadic International had a negative trailing twelve-month return on equity of 68.23% and a negative net margin of 251.43%.

What other stocks do shareholders of Dyadic International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL), Pfizer (PFE), Advanced Micro Devices (AMD), Endeavour Silver (EDR), Mandalay Resources (MND), Ampio Pharmaceuticals (AMPE), Alibaba Group (BABA) and Chimerix (CMRX).

What is Dyadic International's stock symbol?

Dyadic International trades on the NASDAQ under the ticker symbol "DYAI."

How do I buy shares of Dyadic International?

Shares of DYAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dyadic International's stock price today?

One share of DYAI stock can currently be purchased for approximately $2.28.

How much money does Dyadic International make?

Dyadic International (NASDAQ:DYAI) has a market capitalization of $65.69 million and generates $2.93 million in revenue each year. The biotechnology company earns $-9,730,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

How can I contact Dyadic International?

Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The official website for the company is www.dyadic.com. The biotechnology company can be reached via phone at (561) 743-8333, via email at prawson@dyadic.com, or via fax at 561-743-8343.

This page (NASDAQ:DYAI) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -